How Should Companies Select a Local Agent for Medical Device Registration in Vietnam?

How Should Companies Select a Local Agent for Medical Device Registration in Vietnam?

Published: 2026-07-10 17:08 | Updated: 2026-07-10 17:08

Around international medical device registration, document preparation, compliance pathways, and post-market maintenance, this FAQ outlines the issues companies should prioritize in actual projects.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documents and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI Perspective
• Frequently Asked Follow-up Questions
• Continue Reading
• Applicable Boundaries

Key Summary

Direct answer: Companies should first confirm the target country, product risk classification, applicable regulatory pathway, and existing documentation base, then assess technical files, quality management system evidence, labels and instructions for use, local agent arrangements, clinical evidence, and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission to avoid prolonged project timelines caused by unclear classification, missing documents, or unclear authorization arrangements.

For Chinese medical device manufacturers, a more reliable approach is to first complete product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documents can be reused. Vietnam registration typically affects technical files, authorized representative arrangements, importer cooperation, label language, quality management system evidence, and subsequent change maintenance. If a project is advanced only by asking 'which documents must be submitted,' corrections or rework can easily arise in model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends that companies place this question within a unified GHWP member state and multi-country market access strategy, using one reusable core technical file set to support localization in different markets, rather than recreating documents on an ad hoc basis for each country.

This article is compiled from the AIMEILI registration practice question bank, the medical device international registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country regulatory authority and the product documentation base.

Applicable Scenarios and Core Questions

Companies searching for 'how to select a local agent for medical device registration in Vietnam' usually are not looking for a conceptual explanation. They need to judge whether existing documents can support a Vietnam submission, whether a local agent or authorized representative is required, why the timeline may be extended, and which issues may affect the launch plan. Behind this question are often product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for only one country is not enough. A more valuable approach is to first develop reusable versions of core technical files, quality management system evidence, performance verification, clinical evidence, and labels and instructions for use, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, method and duration of body contact, whether it is sterile, whether it is powered, and whether it contains software or has IVD attributes, then determine the risk classification and submission pathway. If the pathway is incorrectly determined, subsequent translation, notarization, authorization, testing, and supplementary documents will all deviate from the correct direction.

For a Vietnam project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documents. If these issues are handled vaguely only in a commercial contract, market control can easily be affected later.

Documents and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality management system evidence, technical files, performance verification reports, risk management documents, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documents.

The key to document quality is not quantity but consistency. Instructions for use claims, model coverage in test reports, the applicable scope of clinical evidence, risk management conclusions, label warnings, and registration application form information must support one another. Regulatory authorities focus on whether the product is safe, effective, and traceable for its intended use, not on whether the company has uploaded many files.

Common Errors

• The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.
• Submitting directly translated NMPA documents without rearranging the evidence according to the Vietnam pathway.
• Too many models and specifications, but insufficient coverage by test reports, clinical evidence, or labels.
• Selecting a local agent only on the basis of sales cooperation, without clearly defining regulatory responsibilities, certificate control, and post-market maintenance responsibilities.
• Inconsistency among labels, instructions for use, promotional materials, and registration document claims, leading to corrections or post-market compliance risks.
• Failure to plan multi-country document reuse in advance, causing repeated preparation for each country and increasing both cost and timeline.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation base, avoiding the discovery of key evidence gaps only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificates, test reports, risk management documents, clinical evaluation, and English instructions for use.
• Confirm the local agent or authorized representative's responsibilities, fees, certificate control, and exit mechanism.
• Establish a target-country gap assessment table, specifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies not view Vietnam registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first, then converting it according to each country's requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than preparing documents on an ad hoc basis country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the document evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documents appear extensive, the project may still experience repeated issues during corrections, agent communication, and post-market maintenance.

Frequently Asked Follow-up Questions

Can domestic documents be used directly for Vietnam registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

A local agent usually participates in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, model and specification, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission dates in one table. This helps identify document gaps in a timely manner and allows management to judge whether the project may affect the launch plan.

For companies that already have registration bases in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which documents must be reissued or supplemented according to country-specific requirements. Labels and instructions for use, clinical evaluation, risk management, performance verification, and quality management system certificates must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a document gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarization, testing, and correction status.
• Arrange post-market maintenance responsibilities in advance.

Quality Management System and Evidence Consistency

From a registration review perspective, quality management system documents are not an isolated certificate. Regulatory authorities usually check whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical documents are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model and specification, or instructions for use version do not match the test report, even if the company has prepared many documents, supplementary explanations may still be required.

Before submission, companies should establish an evidence consistency checklist that maps product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labels and instructions for use version, and quality management system certificate item by item. Although this action appears basic, it can significantly reduce the probability of corrections, especially for projects submitted simultaneously in multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibilities

Vietnam registration projects usually involve local agent, authorized representative, importer, or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels and instructions for use and authorization documents cannot simply be translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact information. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Completing registration does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorization, complaint handling, adverse event reporting, recall processes, label versions, and regulatory update records. Many companies invest substantial effort in obtaining the certificate but neglect post-market maintenance. If a manufacturing address change, model expansion, instructions for use update, or agent replacement occurs later, the certificate can easily become disconnected from market sales.

AIMEILI recommends that companies incorporate this issue into annual international registration plan management: first clarify target market priorities, then establish a reusable document package and country gap list, and finally schedule submission, correction, post-market maintenance, and renewal milestones. The value of this approach is not only to improve registration efficiency in a single country, but more importantly to help companies build replicable overseas compliance capabilities and reduce the cost of starting document preparation from scratch each time they enter a new market.

Continue Reading

Previous: How to Use an ISO 13485 Certificate for Medical Device Registration in Vietnam?

Next: How Are Authorized Representative Responsibilities Divided for Medical Device Registration in Vietnam?

Recommended reading: How to prepare registration documents for medical device registration in Malaysia? How to determine product classification for medical device registration in Malaysia? How to organize technical files for medical device registration in Malaysia? How to localize labels and instructions for use for medical device registration in Malaysia? How to prepare clinical evaluation documents for medical device registration in Malaysia? Can test reports be reused for medical device registration in Malaysia? Return to FAQ Center | News | Contact AIMEILI

Content Review and Applicable Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory information; industry media and project experience are used only as auxiliary judgment.

Applicable boundaries: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country regulatory authority, testing conclusions, or legal opinions.